Novartis China Announces New Indication Approval for Anticancer Drug Tabrecta (Capmatinib) in China

Economic Observer NetworkAccording to The Paper, on September 11, Novartis China announced that its anti-cancer drug Taurida (capmatinib hydrochloride tablets) had successfully received approval for a new indication in China. It will be used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying mesenchymal-epithelial transition factor (MET) exon 14 skipping mutations.